EXHIBIT 99.1
Genentech | NEWS RELEASE |
| | | | |
| | Media Contact: | Debra Charlesworth
Mark Krajnak | (650) 225-2742
(650) 225-2792 |
| | | | |
| | Investor Contact: | Kathee Littrell | (650) 225-1034 |
| | | | |
| | http://www.gene.com |
GENENTECH REPORTS 17 PERCENT INCREASE IN NON-GAAP EARNINGS PER SHARE FOR THIRD QUARTER 2003
- 19 Percent Increase in Product Sales -
SOUTH SAN FRANCISCO, Calif. - October 8, 2003 - Genentech, Inc. (NYSE: DNA) today announced a 17 percent increase in non-GAAP (formerly pro forma) earnings per share for the third quarter of 2003 driven by a 19 percent increase in product sales compared to the third quarter of 2002. Genentech's non-GAAP earnings per share increased 37 percent to 93 cents for the first nine months of 2003.
"We are pleased with Genentech's strong quarter, and we remain on track to meet our 5X5 goals," said Arthur D. Levinson, Ph.D., Genentech's chairman and chief executive officer. "This quarter we also achieved several important milestones, including our launch of Xolair, the FDA panel's unanimous recommendation for approval of Raptiva and the completion of the BLA filing of Avastin."
Note: Genentech's non-GAAP earnings per shareand non-GAAP net income exclude recurring charges related to the 1999 Roche redemption of Genentech's stock, litigation-related special items and the cumulative effect of the change in an accounting principle related to a synthetic lease. This information is itemized in the reconciliation tables below.
For the three months ended September 30, 2003:
- Non-GAAP earnings per share increased 17 percent to 27 cents per share, compared to 23 cents per share for the third quarter of 2002. GAAP earnings per share, including the impact of the recent settlement of litigation with Amgen and the cumulative effect of the change in an accounting principle related to a synthetic lease, increased 71 percent to 29 cents per share compared to 17 cents per share for the third quarter of 2002.
- Non-GAAP net income increased 20 percent to $143.9 million compared to $120.2 million in the third quarter of 2002. GAAP net income, which includes the impact of the settlement with Amgen and the cumulative effect of the accounting change related to a synthetic lease, increased 70 percent to $152.0 million compared to $89.3 million for the third quarter of 2002.
- Operating revenues increased 26 percent to $817.0 million compared to $650.1 million in the third quarter of 2002. This revenue growth was driven primarily by sales of Genentech's BioOncology products, Rituxan® (Rituximab) and Herceptin®(Trastuzumab). Total product sales increased 19 percent to $654.9 million compared to $551.8 million in the third quarter of 2002.
Product Sales
For the third quarter of 2003:
- Sales of marketed products increased 19 percent to $654.9 million compared to $551.8 million in the third quarter of 2002.
- BioOncology sales were 73 percent of total product revenues compared to 71 percent in the third quarter of 2002.
- Rituxan sales increased 26 percent to $371.7 million compared to $293.9 million in the third quarter of 2002.
- Net U.S. sales were $353.6 million, a 31 percent increase versus the third quarter of 2002.
- Ex-U.S. transfer sales were $18.1 million, a 26 percent decrease versus the third quarter of 2002.
- Herceptin sales increased 11 percent to $107.7 million compared to $96.7 million in the third quarter of 2002.
- Growth hormone sales increased 4 percent to $80.6 million compared to $77.4 million in the third quarter of 2002.
- Cardiovascular product sales increased 1 percent to $46.0 million compared to $45.6 million in the third quarter of 2002.
- Pulmozyme® (dornase alfa) Inhalation Solution sales increased 6 percent to $40.4 million compared to $38.2 million in the third quarter of 2002.
- Xolair® (Omalizumab), launched on July 21, had sales of $6.8 million in the quarter.
Contract Revenues
Contract revenues increased to $45.6 million compared to $13.2 million in the third quarter of 2002. The increase in the third quarter of 2003 is primarily due to higher revenues from ongoing collaborations.
Total Costs and Expenses
Costs and expenses increased as anticipated in the third quarter of 2003 as compared to the third quarter of 2002.
For the third quarter of 2003:
- Research and development (R&D) expenses increased to $168.7 million compared to $143.7 million in the third quarter of 2002. R&D expenses as a percentage of operating revenues were 21 percent, compared to 22 percent in the third quarter of 2002.
- Cost of sales increased to $115.7 million from $112.5 million in the third quarter of 2002, primarily due to the increase in product sales. Cost of sales as a percentage of product sales was 18 percent in the third quarter of 2003 as compared to 20 percent in the third quarter of 2002.
- Marketing, general and administrative (MG&A) expenses increased to $209.8 million compared to $121.8 million in the third quarter of 2002, due to ongoing expenses for commercial products, primarily Xolair, and the potential launches of Raptiva and Avastin, increased promotional programs, higher corporate functional and other expenses, and higher royalty expenses. MG&A expenses as a percentage of operating revenues increased 26 percent as compared to 19 percent in the third quarter of 2002.
- Collaboration profit-sharing expenses increased to $119.7 million compared to $90.0 million in the third quarter of 2002. The increase was due primarily to an increased Rituxan profit-sharing expense due to higher Rituxan sales.
"We are on track to meet or exceed our 2003 financial goals, including over $3 billion in revenues and annual non-GAAP EPS growth of at least 20 percent," said Louis J. Lavigne, Jr., Genentech's executive vice president and chief financial officer. "We are continuing to make solid progress toward our 5X5 goals, to be reached by the end of 2005."
Genentech is a leading biotechnology company that discovers, develops, manufactures, and commercializes biotherapeutics for significant unmet medical needs. Sixteen of the currently approved biotechnology products originated from or are based on Genentech science. Genentech manufactures and commercializes 11 biotechnology products in the United States. The company has headquarters in South San Francisco, California, and is traded on the New York Stock Exchange under the symbol DNA. For additional information about the company, please visit http://www.gene.com.
Webcast:
Genentech will be offering a live webcast of a discussion by Genentech management of the earnings and other business results on Wednesday, October 8, 2003 at 2:15 p.m. PT. The live webcast may be accessed on Genentech's website at http://www.gene.com. This webcast will also be available after the call via the website until 5:15 p.m. PT on October 22, 2003. An audio replay of the webcast will be available beginning at 5:15 p.m. PT on October 8, 2003, through 5:15 p.m. PT on October 15, 2003. Access numbers for this replay are: 1-800-642-1687 (US/Canada) and 1-706-645-9291 (international); conference identification number is 2846319.
Genentech Business and Product Development
Events in the Third Quarter 2003
Marketed and Pipeline Product Events
Immunological Disease
In September, Genentech and XOMA Ltd. announced that the U.S. Food and Drug Administration's (FDA) Dermatologic and Ophthalmic Drug Advisory Committee voted unanimously (11-0) to recommend that Raptiva™ (Efalizumab) be approved for the treatment of moderate-to-severe plaque psoriasis in adults age 18 or older. Also, at the American Academy of Dermatology ACADEMY 2003 meeting in late July, Genentech and XOMA announced positive results from two clinical studies evaluating the long-term safety and efficacy of treatment with Raptiva in adults with moderate-to-severe plaque psoriasis.
After a review of the Phase II ulcerative colitis data results, Genentech and Millennium Pharmaceuticals, Inc. have decided not to move forward with a Phase III study. The companies are currently in discussions regarding next steps with the MLN-02 program.
Genentech has decided to discontinue development of Anti-Tissue Factor (ATF) for acute coronary syndrome.
Oncology
Genentech submitted a Biologics License Application (BLA) to the FDA for Avastin as a treatment for first-line metastatic colorectal cancer in combination with chemotherapy. Genentech has also requested Priority Review designation from the FDA. If granted, the target FDA action date would be six months from the completion of the BLA submission. This is Genentech's largest oncology BLA filing to date and the first ever for an anti-angiogenesis therapy for cancer. To date, more than 2,000 patients have been treated with Avastin in clinical studies.
In October, Genentech, OSI Pharmaceuticals Inc. and Roche announced that two first-line Phase III studies of Tarceva™ (erlotinib HCI) plus standard chemotherapy in metastatic non-small cell lung cancer did not meet their primary endpoints of improving overall survival. Genentech and OSI also announced that the first patient has been enrolled in a multi-center, open-label, Phase II clinical trial evaluating the safety and efficacy of Tarceva in patients with malignant glioma (brain cancer). The companies plan to enroll up to 110 patients who have experienced their first relapse of malignant glioma in the trial, which is being conducted by Genentech in collaboration with the Accelerate Brain Cancer Cure (ABC2) Clinical Network of leading neuro-oncology centers.
Genentech, IDEC Pharmaceuticals and Roche began enrolling patients in a Phase III global study of Rituxan for relapsed chronic lymphocytic leukemia.
Enrollment began in a Phase II study of single-agent Omnitarg™ (Pertuzumab) in patients with advanced non-small cell lung cancer who have previously received treatment with one or more chemotherapy regimens. The study will enroll 60 patients.
Vascular Medicine
At the 21st Annual Meeting of the American Society of Retina Specialists in August, Genentech presented positive preliminary six-month data from a Phase Ib/II randomized, single-agent study with Lucentis™ (ranibizumab), formerly known as rhuFab V2, for patients with the wet form of age-related macular degeneration (AMD). Genentech also initiated a second Phase III trial in patients with predominantly classic macular degeneration.
Corporate Events
Genentech announced that it settled its patent litigation with Amgen, Inc. in the U.S. District Court for the Northern District of California. Genentech filed its original complaint against Amgen in 1996. Under the settlement agreement, both parties agreed to dismiss their claims and counterclaims against each other. As part of the settlement, Amgen made a one-time payment to Genentech.
In the third quarter of 2003, Genentech promoted Richard Scheller, Ph.D., to executive vice president, Research and hired Marc Tessier-Lavigne, Ph.D., as senior vice president, Research Drug Discovery. The company also announced the promotions of Diane Parks to senior vice president and general manager, Specialty Biotherapeutics and Managed Care; Andrew C. Chan, M.D., Ph.D., to vice president, Research-Immunology; Vishva Dixit, M.D., to vice president, Research-Molecular Oncology; and David Logan to vice president, Specialty Therapeutics.
The statements made in this press release relating to Genentech's 2003 financial goals, including growth in revenues and non-GAAP EPS, are forward-looking and actual results could differ materially. Among other things, Genentech's growth in revenues and non-GAAP EPS could be impacted by a number of factors, including FDA actions or delays or failure to receive FDA approval, competition, pricing, the ability to supply product, product withdrawals, new product approvals and launches, achieving sales revenue consistent with internal forecasts, unanticipated expenses such as litigation or legal settlement expenses or equity securities writedowns, costs of sales, R&D expenses, fluctuations in contract revenues and royalties, and fluctuations in tax and interest rates.
# # #
GENENTECH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
(unaudited) |
| |
| | | Three Months
Ended September 30, |
| | |
| | | 2003 | | 2002(7) |
| | | | |
| | | GAAP(1) | | Difference | | Non-GAAP(2) | | GAAP(1) | | Difference | | Non-GAAP(2) |
| | | | | | | | | | | | |
Revenues: | | | | | | | | | | | | | | | | | |
Product sales | $ | 654,948 | | | | | $ | 654,948 | | $ | 551,823 | | | | | $ | 551,823 |
Royalties | | 116,535 | | | | | | 116,535 | | | 85,082 | | | | | | 85,082 |
Contract revenue | | 45,561 | | | | | | 45,561 | | | 13,233 | | | | | | 13,233 |
| | | | | | | | | | | | | | | | | | |
Total operating revenues | | 817,044 | | | | | | 817,044 | | | 650,138 | | | | | | 650,138 |
| | | | | | | | | | | | | | | | | | |
Costs and expenses: | | | | | | | | | | | | | | | | | |
Cost of sales | | 115,673 | | | | | | 115,673 | | | 112,481 | | | | | | 112,481 |
Research and development | | 168,707 | | | | | | 168,707 | | | 143,659 | | | | | | 143,659 |
Marketing, general and administrative | | 209,860 | | | | | | 209,860 | | | 121,807 | | | | | | 121,807 |
Collaboration profit sharing | | 119,676 | | | | | | 119,676 | | | 90,048 | | | | | | 90,048 |
Recurring charges related to redemption | | 38,586 | | $ | (38,586) | (3) | | - | | | 38,928 | | $ | (38,928) | (3) | | - |
Special items: litigation-related | | (131,617) | | | 131,617 | (4) | | - | | | 12,512 | | | (12,512) | (4) | | - |
| | | | | | | | | | | | |
Total costs and expenses | | 520,885 | | | 93,031 | | | 613,916 | | | 519,435 | | | (51,440) | | | 467,995 |
| | | | | | | | | | | | | | | | | | | |
Operating margin | | 296,159 | | | (93,031) | | | 203,128 | | | 130,703 | | | 51,440 | | | 182,143 |
| | | | | | | | | | | | | | | | | | | |
Other income, net(6) | | 15,884 | | | - | | | 15,884 | | | 1,423 | | | - | | | 1,423 |
| | | | | | | | | | | | | | | | | | | |
Income (loss) before taxes and cumulative
effect of accounting change | |
312,043
| | |
(93,031)
| | |
219,012
| | | 132,126 | | |
51,440
| | | 183,566 |
Income tax provision (benefit) | | 112,407 | | | (37,316) | | | 75,091 | | | 42,822 | | | 20,563 | | | 63,385 |
| | | | | | | | | | | | |
Income (loss) before cumulative effect of
accounting change | |
199,636
| | |
(55,715)
| | |
143,921
| | |
89,304
| | |
30,877
| | |
120,181
|
Cumulative effect of accounting change,
net of tax | |
(47,655)
| | |
47,655
|
(5)
| |
- -
| | |
- -
| | |
- -
| | |
- -
|
| | | | | | | | | | | | | | | | | | |
Net income (loss) | $ | 151,981 | | $ | (8,060) | | $ | 143,921 | | $ | 89,304 | | $ | 30,877 | | $ | 120,181 |
| | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
Earnings (loss) per share: | | | | | | | | | | | | | | | | | |
Basic:
| Earnings (loss) before cumulative
effect of accounting change |
$
|
0.38
| |
$
|
(0.10)
| |
$
|
0.28
| |
$
|
0.17
| |
$
|
0.06
| |
$
|
0.23
|
| | Cumulative effect of accounting
change, net of tax | |
(0.09)
| | |
0.09
| | |
- -
| | |
- -
| | |
- -
| | |
- -
|
| | | | | | | | | | | | |
| | Net earnings (loss) per share | $ | 0.29 | | $ | (0.01) | | $ | 0.28 | | $ | 0.17 | | $ | 0.06 | | $ | 0.23 |
| | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | |
Diluted:
| Earnings (loss) before cumulative
effect of accounting change |
$
|
0.38
| |
$
|
(0.11)
| |
$
|
0.27
| |
$
|
0.17
| |
$
|
0.06
| |
$
|
0.23
|
| | Cumulative effect of accounting
change, net of tax | |
(0.09)
| | |
0.09
| | |
- -
| | |
- -
| | |
- -
| | |
- -
|
| | | | | | | | | | | | |
| | Net earnings (loss) per share | $ | 0.29 | | $ | (0.02) | | $ | 0.27 | | $ | 0.17 | | $ | 0.06 | | $ | 0.23 |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
Weighted average shares used to compute
earnings per share: | | | | | | | | | | | | | | | | | |
Basic | | 520,381 | | | | | | 520,381 | | | 516,025 | | | | | | 516,025 |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
Diluted | | 532,786 | | | | | | 532,786 | | | 519,429 | | | | | | 519,429 |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
___________________
(1) | | Reflects operating results in accordance with U.S. generally accepted accounting principles (or GAAP). |
(2) | | Non-GAAP amounts exclude litigation-related special items, recurring charges related to the 1999 redemption of Genentech's Special Common Stock, and the cumulative effect of a change in accounting principle related to our adoption of Financial Accounting Standards Board Interpretation No. 46, "Consolidation of Variable Interest Entities," (or FIN 46), net of tax effects. |
(3) | | Amount represents the amortization of other intangible assets related to the 1999 redemption of Genentech's Special Common Stock. |
(4) | | Represents amounts received in Q3 2003 related to the Amgen patent litigation settlement, net of accrued interest and costs related to a surety bond for the City of Hope trial judgment in Q3 2003 and 2002. |
(5) | | Amount represents the cumulative effect of the accounting change related to our adoption of FIN 46. |
(6) | | As part of our strategic alliance efforts, we invest in equity securities of certain biotechnology companies with which we have collaborative agreements. "Other income, net" includes realized gains from the sale of certain of these biotechnology marketable equity securities and realized losses on other-than-temporary declines in the fair value of certain of these biotechnology marketable equity securities. In addition, "Other income, net" includes interest income and interest expense. For further detail, refer to our web site at www.gene.com. |
(7) | | Certain reclassifications of prior year amounts have been made to conform with the current year presentation. |
GENENTECH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
(unaudited) |
| |
| | | Nine Months
Ended September 30, |
| | |
| | | 2003 | | 2002(7) |
| | | | |
| | | GAAP(1) | | Difference | | Non-GAAP(2) | | GAAP(1) | | Difference | | Non-GAAP(2) |
| | | | | | | | | | | | |
Revenues: | | | | | | | | | | | | | | | | | |
Product sales | $ | 1,897,754 | | | | | $ | 1,897,754 | | $ | 1,551,899 | | | | | $ | 1,551,899 |
Royalties | | 352,597 | | | | | | 352,597 | | | 252,460 | | | | | | 252,460 |
Contract revenue | | 116,078 | | | | | | 116,078 | | | 36,104 | | | | | | 36,104 |
| | | | | | | | | | | | | | | | | | |
Total operating revenues | | 2,366,429 | | | | | | 2,366,429 | | | 1,840,463 | | | | | | 1,840,463 |
| | | | | | | | | | | | | | | | | |
Costs and expenses: | | | | | | | | | | | | | | | | | |
Cost of sales | | 353,921 | | | | | | 353,921 | | | 321,792 | | | | | | 321,792 |
Research and development | | 506,343 | | | | | | 506,343 | | | 438,272 | | | | | | 438,272 |
Marketing, general and administrative | | 531,340 | | | | | | 531,340 | | | 362,898 | | | | | | 362,898 |
Collaboration profit sharing | | 323,530 | | | | | | 323,530 | | | 246,216 | | | | | | 246,216 |
Recurring charges related to redemption | | 115,758 | | $ | (115,758) | (3) | | - | | | 116,784 | | $ | (116,784) | (3) | | - |
Special items: litigation-related | | (105,008) | | | 105,008 | (4) | | - | | | 530,512 | | | (530,512) | (4) | | - |
| | | | | | | | | | | | |
Total costs and expenses | | 1,725,884 | | | (10,750) | | | 1,715,134 | | | 2,016,474 | | | (647,296) | | | 1,369,178 |
| | | | | | | | | | | | | | | | | | |
Operating margin | | 640,545 | | | 10,750 | | | 651,295 | | | (176,011) | | | 647,296 | | | 471,285 |
| | | | | | | | | | | | | | | | | | |
Other income, net(6) | | 72,456 | | | - | | | 72,456 | | | 66,658 | | | - | | | 66,658 |
| | | | | | | | | | | | | | | | | | |
Income (loss) before taxes and cumulative
effect of accounting change | |
713,001
| | |
10,750
| | |
723,751
| | |
(109,353)
| | |
647,296
| | |
537,943
|
Income tax provision (benefit) | | 229,549 | | | 4,196 | | | 233,745 | | | (80,312) | | | 258,906 | | | 178,594 |
| | | | | | | | | | | | |
Income (loss) before cumulative effect of
accounting change | |
483,452
| | |
6,554
| | |
490,006
| | |
(29,041)
| | |
388,390
| | |
359,349
|
Cumulative effect of accounting change,
net of tax | |
(47,655)
| | |
47,655
|
(5)
| |
- -
| | |
- -
| | |
- -
| | |
- -
|
| | | | | | | | | | | | | | | | | |
Net income (loss) | $ | 435,797 | | $ | 54,209 | | $ | 490,006 | | $ | (29,041) | | $ | 388,390 | | $ | 359,349 |
| | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
Earnings (loss) per share: | | | | | | | | | | | | | | | | | |
Basic:
| Earnings (loss) before cumulative
effect of accounting change |
$
|
0.94
| |
$
|
0.01
| |
$
|
0.95
| |
$
|
(0.06)
| |
$
|
0.75
| |
$
|
0.69
|
| | Cumulative effect of accounting
change, net of tax | |
(0.09)
| | |
0.09
| | |
- -
| | |
- -
| | |
- -
| | |
- -
|
| | | | | | | | | | | | | | | | | | |
| | Net earnings (loss) per share | $ | 0.85 | | $ | 0.10 | | $ | 0.95 | | $ | (0.06) | | $ | 0.75 | | $ | 0.69 |
| | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | |
Diluted:
| Earnings (loss) before cumulative
effect of accounting change | $ |
0.92
| |
$
|
0.01
| |
$
|
0.93
| | $ |
(0.06)
| | $ |
0.74
| | $ |
0.68
|
| | Cumulative effect of accounting
change, net of tax | |
(0.09)
| | |
0.09
| | |
- -
| | |
- -
| | |
- -
| | |
- -
|
| | | | | | | | | | | | | | | | | | |
| | Net earnings (loss) per share | $ | 0.83 | | $ | 0.10 | | $ | 0.93 | | $ | (0.06) | | $ | 0.74 | | $ | 0.68 |
| | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
Weighted average shares used to compute
earnings per share: | | | | | | | | | | | | | | | | | |
Basic | | 515,070 | | | | | | 515,070 | | | 520,889 | | | | | | 520,889 |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
Diluted | | 525,825 | | | | | | 525,825 | | | 520,889 | | | | | | 526,000 |
| | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | |
___________________
(1) | | Reflects operating results in accordance with U.S. generally accepted accounting principles (or GAAP). |
(2) | | Non-GAAP amounts exclude litigation-related special items, recurring charges related to the 1999 redemption of Genentech's Special Common Stock, and the cumulative effect of a change in accounting principle related to our adoption of Financial Accounting Standards Board Interpretation No. 46, "Consolidation of Variable Interest Entities," (or FIN 46), net of tax effects. |
(3) | | Amount represents the amortization of other intangible assets related to the 1999 redemption of Genentech's Special Common Stock. |
(4) | | Represents amounts received in Q3 2003 related to the Amgen patent litigation settlement, net of accrued interest and costs related to a surety bond for the City of Hope trial judgment in 2003 and 2002. |
(5) | | Amount represents the cumulative effect of the accounting change related to our adoption of FIN 46. |
(6) | | As part of our strategic alliance efforts, we invest in equity securities of certain biotechnology companies with which we have collaborative agreements. "Other income, net" includes realized gains from the sale of certain of these biotechnology marketable equity securities and realized losses on other-than-temporary declines in the fair value of certain of these biotechnology marketable equity securities. In addition, "Other income, net" includes interest income and interest expense. For further detail, refer to our web site at www.gene.com. |
(7) | | Certain reclassifications of prior year amounts have been made to conform with the current year presentation. |
GENENTECH, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
(unaudited) |
| | |
| | |
| | September 30, |
| |
| | 2003 | | 2002 |
| | | |
Selected balance sheet data: | | | | | |
Cash and short-term investments | $ | 1,387,223 | | $ | 1,124,145 |
Accounts receivable - product sales, net | | 286,160 | | | 189,128 |
Accounts receivable - royalties, net | | 151,884 | | | 101,300 |
Accounts receivable - other, net | | 62,707 | | | 11,663 |
Inventories | | 423,439 | | | 394,593 |
Long-term marketable securities and other | | 1,306,143 | | | 1,049,799 |
Property, plant and equipment, net | | 1,540,849 | (5) | | 1,017,121 |
Goodwill | | 1,334,219 | | | 1,334,219 |
Other intangible assets | | 827,109 | | | 965,246 |
Other long-term assets | | 793,104 | (4) | | 277,654 |
Total assets | | 8,395,745 | | | 6,673,424 |
Total current liabilities | | 728,043 | | | 588,216 |
Total liabilities | | 2,151,699 | (6) | | 1,372,646 |
Total stockholders' equity | | 6,244,046 | | | 5,300,778 |
| | | | | | |
Year-to-date: | | | | | |
Capital expenditures | $ | 211,245 | | $ | 244,626 |
| | | | | | |
| | | | | | |
Total GAAP(1) depreciation and amortization expense | | 220,926 | | | 205,029 |
Less: redemption related amortization expense(3) | | (115,758) | | | (116,784) |
| | | | | |
Non-GAAP(2) depreciation and amortization expense | $ | 105,168 | | $ | 88,245 |
| | | | | |
| | | | | |
| | | | | |
___________________
